Caribou Biosciences Financials
| CRBU Stock | USD 1.98 0.02 1.02% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.04 | 11.9723 |
|
|
Investors should never underestimate Caribou Biosciences' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Caribou Biosciences' cash flow, debt, and profitability to make informed and accurate decisions about investing in Caribou Biosciences.
Net Income |
|
Caribou | Select Account or Indicator |
Understanding current and past Caribou Biosciences Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Caribou Biosciences' financial statements are interrelated, with each one affecting the others. For example, an increase in Caribou Biosciences' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Caribou Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Caribou Biosciences. Check Caribou Biosciences' Beneish M Score to see the likelihood of Caribou Biosciences' management manipulating its earnings.
Caribou Biosciences Stock Summary
Caribou Biosciences competes with Intellia Therapeutics, Editas Medicine, Crispr Therapeutics, Verve Therapeutics, and Beam Therapeutics. Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. The company was incorporated in 2011 and is headquartered in Berkeley, California. Caribou Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US1420381089 |
| CUSIP | 142038108 |
| Location | California; U.S.A |
| Business Address | 2929 7th Street, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | cariboubio.com |
| Phone | 510 982 6030 |
| Currency | USD - US Dollar |
Caribou Biosciences Key Financial Ratios
| Return On Equity | -0.44 | ||||
| Operating Margin | (16.67) % | ||||
| Price To Sales | 15.62 X | ||||
| Revenue | 34.48 M | ||||
| Gross Profit | (68.38 M) |
Caribou Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Caribou Biosciences's current stock value. Our valuation model uses many indicators to compare Caribou Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Caribou Biosciences competition to find correlations between indicators driving Caribou Biosciences's intrinsic value. More Info.Caribou Biosciences is rated fourth in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Caribou Biosciences' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Caribou Biosciences by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Caribou Biosciences Systematic Risk
Caribou Biosciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Caribou Biosciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Caribou Biosciences correlated with the market. If Beta is less than 0 Caribou Biosciences generally moves in the opposite direction as compared to the market. If Caribou Biosciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Caribou Biosciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Caribou Biosciences is generally in the same direction as the market. If Beta > 1 Caribou Biosciences moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Caribou Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Caribou Biosciences' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Caribou Biosciences growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Caribou Biosciences November 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Caribou Biosciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Caribou Biosciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of Caribou Biosciences based on widely used predictive technical indicators. In general, we focus on analyzing Caribou Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Caribou Biosciences's daily price indicators and compare them against related drivers.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 28.53 | |||
| Value At Risk | (6.63) | |||
| Potential Upside | 7.42 |
Additional Tools for Caribou Stock Analysis
When running Caribou Biosciences' price analysis, check to measure Caribou Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Caribou Biosciences is operating at the current time. Most of Caribou Biosciences' value examination focuses on studying past and present price action to predict the probability of Caribou Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Caribou Biosciences' price. Additionally, you may evaluate how the addition of Caribou Biosciences to your portfolios can decrease your overall portfolio volatility.